Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

682 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry.
Marchesi F, Salmanton-García J, Buquicchio C, Itri F, Besson C, Dávila-Valls J, Martín-Pérez S, Fianchi L, Rahimli L, Tarantini G, Grifoni FI, Sciume M, Labrador J, Cordoba R, López-García A, Fracchiolla NS, Farina F, Ammatuna E, Cingolani A, García-Bordallo D, Gräfe SK, Bilgin YM, Dargenio M, González-López TJ, Guidetti A, Lahmer T, Lavilla-Rubira E, Méndez GA, Prezioso L, Schönlein M, Van Doesum J, Wolf D, Hersby DS, Magyari F, Van Praet J, Petzer V, Tascini C, Falces-Romero I, Glenthøj A, Cornely OA, Pagano L. Marchesi F, et al. Among authors: tarantini g. J Hematol Oncol. 2023 Apr 1;16(1):32. doi: 10.1186/s13045-023-01423-7. J Hematol Oncol. 2023. PMID: 37005697 Free PMC article.
A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin's lymphoma.
Gaudio F, Loseto G, Bozzoli V, Scalzulli PR, Mazzone AM, Tonialini L, Fesce V, Quintana G, De Santis G, Masciopinto P, Arcuti E, Clemente F, Scardino S, Tarantini G, Pastore D, Melillo L, Pavone V, Maggi A, Carella AM, Di Renzo N, Guarini A, Musto P. Gaudio F, et al. Among authors: tarantini g. Ann Hematol. 2023 Feb;102(2):385-392. doi: 10.1007/s00277-023-05100-0. Epub 2023 Jan 16. Ann Hematol. 2023. PMID: 36645458
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.
Gentile M, Vigna E, Palmieri S, Galli M, Derudas D, Mina R, Della Pepa R, Zambello R, Martino EA, Bruzzese A, Mangiacavalli S, Zamagni E, Califano C, Musso M, Conticello C, Cerchione C, Mele G, Di Renzo N, Offidani M, Tarantini G, Casaluci GM, Rago A, Ria R, Uccello G, Barilà G, Palumbo G, Pompa A, Vincelli D, Brunori M, Accardi F, Amico V, Amendola A, Fontana R, Bongarzoni V, Rossini B, Cotzia E, Gozzetti A, Rizzi R, Sgherza N, Ferretti E, Bertuglia G, Nappi D, Petrucci MT, Di Raimondo F, Neri A, Morabito F, Musto P. Gentile M, et al. Among authors: tarantini g. Haematologica. 2024 Jan 1;109(1):245-255. doi: 10.3324/haematol.2023.283251. Haematologica. 2024. PMID: 37439329 Free PMC article.
Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by "rete ematologica pugliese".
Mele G, Di Renzo N, Cascavilla N, Carella AM, Guarini A, Mazza P, Melillo L, Pavone V, Tarantini G, Curci P, Falcone AP, Germano C, Mele A, Merchionne F, Palazzo G, Palumbo G, Quinto AM, Reddiconto G, Rossini B, Spina A, Sgherza N, Specchia G, Musto P, Pastore D. Mele G, et al. Among authors: tarantini g. Leuk Lymphoma. 2023 Oct;64(10):1715-1718. doi: 10.1080/10428194.2023.2232487. Epub 2023 Jul 7. Leuk Lymphoma. 2023. PMID: 37417467 No abstract available.
A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma.
Arcari A, Rigacci L, Tucci A, Puccini B, Usai SV, Cavallo F, Fabbri A, Balzarotti M, Pelliccia S, Luminari S, Pennese E, Zilioli VR, Mahmoud AM, Musuraca G, Marino D, Sartori R, Botto B, Gini G, Zanni M, Hohaus S, Tarantini G, Flenghi L, Tani M, Di Rocco A, Merli M, Vallisa D, Pagani C, Nassi L, Dessì D, Ferrero S, Cencini E, Bernuzzi P, Mammi C, Marcheselli L, Tabanelli V, Spina M, Merli F. Arcari A, et al. Among authors: tarantini g. Blood Adv. 2023 Aug 8;7(15):4160-4169. doi: 10.1182/bloodadvances.2023009839. Blood Adv. 2023. PMID: 37276080 Free PMC article.
A very rare cause of leukoencephalopathy: Lymphomatosis cerebri.
Giorelli M, Altomare S, Aniello MS, Bruno MC, Leone R, Liuzzi D, Ingravallo G, Fazio PD, Scarabino T, Tarantini G. Giorelli M, et al. Among authors: tarantini g. Intractable Rare Dis Res. 2023 May;12(2):118-121. doi: 10.5582/irdr.2022.01134. Intractable Rare Dis Res. 2023. PMID: 37287655 Free PMC article.
Transcatheter Aortic Valve Replacement in Low-Surgical Risk Patients: an updated metanalysis of extended follow-up randomized controlled trials.
Pietro GD, Improta R, De Filippo O, Bruno F, Birtolo LI, Tocci M, Fabris T, Saade W, Colantonio R, Celli P, Sardella G, Esposito G, Tarantini G, Massimo M, D'Ascenzo F. Pietro GD, et al. Among authors: tarantini g. Am J Cardiol. 2024 May 8:S0002-9149(24)00358-8. doi: 10.1016/j.amjcard.2024.05.005. Online ahead of print. Am J Cardiol. 2024. PMID: 38729335
Unveiling the Hidden Danger of Prosthesis Infolding.
Tarantini G, Cardaioli F. Tarantini G, et al. Am J Cardiol. 2024 May 3:S0002-9149(24)00324-2. doi: 10.1016/j.amjcard.2024.04.043. Online ahead of print. Am J Cardiol. 2024. PMID: 38705252 No abstract available.
Long-term efficacy and safety of tailored immunosuppressive therapy in immune-mediated biopsy-proven myocarditis: A propensity-weighted study.
Caforio ALP, Giordani AS, Baritussio A, Marcolongo D, Vicenzetto C, Tarantini G, Napodano M, Toscano G, Gregori D, Brigiari G, Bartolotta P, Carturan E, De Gaspari M, Rizzo S, Basso C, Iliceto S, Marcolongo R. Caforio ALP, et al. Among authors: tarantini g. Eur J Heart Fail. 2024 Apr 17. doi: 10.1002/ejhf.3220. Online ahead of print. Eur J Heart Fail. 2024. PMID: 38629741
682 results